OCGN Ocugen Inc
Company Analysis
Latest News
🔴 Ocugen is trading 10.13% down today with no clear company-specific explanation
Ocugen is trading 10.13% down at $0.80, with no clear company-specific news explaining the decline. - Today’s OCU400 licensing announcement covers exclusive...
🔴 Ocugen is trading 5% down on October 14, 2026 as biotech and U.S. indexes fall
Ocugen is trading at $0.84, with a -5.13% change during the October 14 session amid sector and broader-market pressure. - Ocugen announced an OCU400 licensing...
🟢 Ocugen is trading 5% up in pre-market
Ocugen is trading at $0.93, 5.03% up in pre-market on October 14, with no confirmed catalyst identified. - The October 13 close was $0.89. - No fresh company...
🔴 Ocugen is trading 5% down — no direct catalyst identified
Ocugen is trading 5.17% lower at $0.90, with no direct company-specific catalyst identified. - The biotech sector is under pressure, with XBI down 2.01% during...
🔴 Ocugen is trading 6.1% down with no clear company-specific catalyst
Ocugen is trading 6.1% down at $0.92 on October 9, 2026, with no specific company catalyst identified for the decline. - Company news shows a...
🟢 Ocugen is trading 7.69% up
Ocugen is trading 7.69% up at $1.12 as of 9:44 a.m. EST on October 6, 2026; the move’s catalyst remains unclear. - The company’s latest release lists...
🔴 Ocugen is trading 5% down
Ocugen is trading at $1.03, down 5.05%, with no clear company-specific catalyst identified for the decline. - On September 30, Ocugen announced...
🟢 Ocugen is trading 5% up; no confirmed catalyst
Ocugen is trading 5.05% up at $1.08 on September 29, 2026; no direct catalyst for the intraday gain has been confirmed. - On September 25, Ocugen announced...
🟢 Ocugen is trading 5% up today after provisional OCU400 approval in The Bahamas
Ocugen is trading 5% higher at $1.05 after announcing provisional approval and priority designation in The Bahamas for OCU400, its investigational retinitis...
🔴 Ocugen is trading 5% down today after shareholders adjourned 250-million-share increase vote
Ocugen is trading at $0.99, down 5%, after shareholders adjourned a special-meeting vote on increasing authorized common stock by 250 million shares. - The...
🟢 Ocugen rises 6.2% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Ocugen falls 5.2% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Ocugen CEO sells $589,000 in stock, following clinical trial setback
Ocugen CEO and Director Shankar Musunuri sold $589,109 in common stock on September 9, 2026. The transactions were executed under a Rule 10b5-1 trading plan...
🟢 Ocugen is trading 6.08% up in pre-market after a $40 million stock sale
Ocugen is trading 6.08% up at $1.13 after announcing a $40 million stock sale. - Shares partially recovered from a 19.92% decline on September 9. - The prior...
Ocugen Raises $40 Million to Fight Blindness, but Can Fresh Cash Outrun a Growing Dilution Problem and Shaky Trial Data?
Shares of Ocugen bounced +8% to $1.15 on news of a $40 million stock sale, a partial recovery after the stock cratered nearly 20% in the prior session. The...
🟢 Ocugen is trading 8% up today in after-hours trading after a $40 million registered direct offering
Ocugen is trading at $1.15 (+7.98%) in after-hours trading after announcing a $40 million registered direct offering. - The offering sells 20 million shares...
Ocugen raises $40 million, funding late-stage blindness gene therapy trials
Ocugen, Inc. entered an agreement for a registered direct offering to raise approximately $40 million in gross proceeds. The company will sell 20 million...
🔴 Ocugen is trading 12.4% down today
Ocugen is trading 12.4% down at $1.17 after no clear company-specific catalyst was identified for September 9, 2026. - Ocugen is scheduled to present its...
🔴 Ocugen is trading 7.89% down today with no clear company-specific catalyst
Ocugen is trading 7.89% down now at $1.23 after no clear company-specific catalyst was identified for September 9, 2026. - Ocugen is scheduled to present its...
Ocugen Doses First Patient in Phase 3 Trial for Blindness Treatment
Ocugen dosed the first patient in its global Phase 3 registrational trial, ArMaDa3. This study evaluates OCU410 as a one-time gene therapy for geographic...